The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo

Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 93; no. 6
Main Authors de Freitas, Lorena F D, Oliveira, Rafael P, Miranda, Mariana C G, Rocha, Raíssa P, Barbosa-Stancioli, Edel F, Faria, Ana Maria C, da Fonseca, Flávio G
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 15.03.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 T cells. CD4 T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses. Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
AbstractList Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses in vivo , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 + T cells. CD4 + T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host’s immune responses. IMPORTANCE Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 T cells. CD4 T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses. Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. ABSTRACT Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses in vivo , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 + T cells. CD4 + T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host’s immune responses. IMPORTANCE Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
Author Faria, Ana Maria C
da Fonseca, Flávio G
Oliveira, Rafael P
Rocha, Raíssa P
de Freitas, Lorena F D
Barbosa-Stancioli, Edel F
Miranda, Mariana C G
Author_xml – sequence: 1
  givenname: Lorena F D
  surname: de Freitas
  fullname: de Freitas, Lorena F D
  organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
– sequence: 2
  givenname: Rafael P
  surname: Oliveira
  fullname: Oliveira, Rafael P
  organization: Instituto Federal do Paraná, Palmas, PR, Brazil
– sequence: 3
  givenname: Mariana C G
  surname: Miranda
  fullname: Miranda, Mariana C G
  organization: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
– sequence: 4
  givenname: Raíssa P
  surname: Rocha
  fullname: Rocha, Raíssa P
  organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
– sequence: 5
  givenname: Edel F
  surname: Barbosa-Stancioli
  fullname: Barbosa-Stancioli, Edel F
  organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
– sequence: 6
  givenname: Ana Maria C
  surname: Faria
  fullname: Faria, Ana Maria C
  organization: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
– sequence: 7
  givenname: Flávio G
  surname: da Fonseca
  fullname: da Fonseca, Flávio G
  email: fdafonseca@icb.ufmg.br
  organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil fdafonseca@icb.ufmg.br
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30567985$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1r3DAQhkVJaTZpbz0XHXuoU8m2tPKlEDb92JDSQpalNyHLo0ZFlhxJTtk_k98a5ZPkNDDz8r4z8xygPR88IPSekiNKa_H5dLs-IjXtaEXFK7SgpBMVY7TdQwtC6rpijfizjw5S-kcIbVvevkH7DWF82Qm2QNebC8BbG2cHXgMOBp9YYyCCz3irtLbeqrt5wuc5KusTXqeiiaCz2-HfMUwhZhu8cjgHXNxsxMe9dTbv8Cbgk_Dfj2GYncqAzyfQ1liNV-Bc9RMGW7oDXo_j7AGvwjipmMcSXUJ8Sb0Kb9Fro1yCdw_1EG2-fd2sflRnv76vV8dnlW5EmyvVc357kiBs4D1Xvebdki1pw0zDlO6XRNS6V9CbvulIR4Uh0NWcGUP0YKA5RF_ubae5H2HQZYWonJyiHVXcyaCsfDnx9kL-DVeSt-WnnBaDjw8GMVzOkLIcbdLlSuUhzEnWlHVNgURYkX66l-oYUopgnmIokbdEZSEq74hKKor8w_PVnsSPCJsb7e-hzg
CitedBy_id crossref_primary_10_3390_microorganisms9010042
crossref_primary_10_1002_cti2_1392
crossref_primary_10_1186_s12985_021_01595_z
crossref_primary_10_3389_fimmu_2019_01780
crossref_primary_10_1016_j_celrep_2024_113882
crossref_primary_10_1016_j_mehy_2020_109556
crossref_primary_10_3389_fimmu_2022_867918
crossref_primary_10_3390_biomedicines10092289
Cites_doi 10.1016/S1473-3099(15)00362-X
10.4137/CMO.S7654
10.1128/JVI.74.2.923-933.2000
10.1128/jvi.67.12.7623-7628.1993
10.3201/eid0706.010602
10.1016/j.antiviral.2009.06.006
10.1128/JVI.05779-11
10.1146/annurev.iy.11.040193.001203
10.1128/JVI.00756-10
10.1016/j.vaccine.2013.06.073
10.1038/nm1128
10.1128/JVI.74.16.7651-7655.2000
10.1016/j.vaccine.2011.08.098
10.1016/j.vaccine.2008.09.016
10.1038/sj.cgt.7700937
10.1007/s00705-003-0006-z
10.4049/jimmunol.172.10.6265
10.1016/j.vaccine.2006.02.012
10.1186/1471-2334-1-9
10.1189/jlb.4MA0815-376RR
10.1128/JVI.01997-08
10.1038/ni1179
10.1086/592507
10.1371/journal.pone.0007428
10.1006/viro.1998.9123
10.1038/icb.2014.10
10.1055/s-0028-1108143
10.1099/0022-1317-79-5-1159
10.1128/JVI.01042-17
10.1128/JVI.00945-06
10.1099/0022-1317-72-5-1031
10.1089/10430340460745757
10.1099/0022-1317-1-3-399
10.1371/journal.pone.0149364
10.1177/095632020101200105
10.1128/jvi.70.12.8301-8309.1996
10.1007/s00436-008-1150-x
10.1002/9780471729259.mca04is17
10.1099/vir.0.055921-0
10.1371/journal.pone.0114374
10.1371/journal.pone.0003043
10.1128/JVI.01894-15
10.1038/cmi.2014.128
10.1155/2012/974067
10.1128/JVI.02797-14
10.1073/pnas.89.22.10847
10.1073/pnas.0406381102
10.1038/s41598-017-08719-y
10.1111/j.0818-9641.2004.01243.x
10.1128/JVI.79.16.10397-10407.2005
10.1099/vir.0.19285-0
ContentType Journal Article
Copyright Copyright © 2019 American Society for Microbiology.
Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology
Copyright_xml – notice: Copyright © 2019 American Society for Microbiology.
– notice: Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1128/JVI.02191-18
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Modulation of Host Immunity by Vaccinia Virus Strains
EISSN 1098-5514
Editor Sandri-Goldin, Rozanne M.
Editor_xml – sequence: 1
  givenname: Rozanne M.
  surname: Sandri-Goldin
  fullname: Sandri-Goldin, Rozanne M.
ExternalDocumentID 10_1128_JVI_02191_18
30567985
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: NA
GroupedDBID ---
-~X
0R~
18M
29L
2WC
39C
4.4
53G
5GY
5RE
5VS
85S
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
N9A
NPM
O9-
OK1
P2P
RHF
RHI
RNS
RPM
RSF
TR2
UCJ
UPT
W2D
W8F
WH7
WOQ
YQT
~02
~KM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c384t-ab660567805d6b6abc69757135f35acb7082cbaebfb390918f0e9265ff0cdfe3
IEDL.DBID RPM
ISSN 0022-538X
IngestDate Tue Sep 17 21:15:39 EDT 2024
Fri Oct 25 07:51:43 EDT 2024
Thu Sep 12 17:16:58 EDT 2024
Sat Sep 28 08:29:17 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Western Reserve strain
MVA
Lister strain
vaccinia virus
mouse model
modulation of the host immune response
Language English
License Copyright © 2019 American Society for Microbiology.
All Rights Reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c384t-ab660567805d6b6abc69757135f35acb7082cbaebfb390918f0e9265ff0cdfe3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation de Freitas LFD, Oliveira RP, Miranda MCG, Rocha RP, Barbosa-Stancioli EF, Faria AMC, da Fonseca FG. 2019. The virulence of different vaccinia virus strains is directly proportional to their ability to downmodulate specific cell-mediated immune compartments in vivo. J Virol 93:e02191-18. https://doi.org/10.1128/JVI.02191-18.
OpenAccessLink https://jvi.asm.org/content/jvi/93/6/e02191-18.full.pdf
PMID 30567985
PQID 2159321905
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6401461
proquest_miscellaneous_2159321905
crossref_primary_10_1128_JVI_02191_18
pubmed_primary_30567985
PublicationCentury 2000
PublicationDate 2019-03-15
PublicationDateYYYYMMDD 2019-03-15
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2019
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_28_2
Mayr A (e_1_3_2_5_2) 1978; 167
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
Nicol MP (e_1_3_2_19_2) 2010; 12
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
Jelinkova A (e_1_3_2_49_2) 1973; 17
e_1_3_2_55_2
e_1_3_2_2_2
References_xml – ident: e_1_3_2_20_2
  doi: 10.1016/S1473-3099(15)00362-X
– ident: e_1_3_2_21_2
  doi: 10.4137/CMO.S7654
– ident: e_1_3_2_40_2
  doi: 10.1128/JVI.74.2.923-933.2000
– ident: e_1_3_2_54_2
  doi: 10.1128/jvi.67.12.7623-7628.1993
– ident: e_1_3_2_11_2
  doi: 10.3201/eid0706.010602
– ident: e_1_3_2_3_2
  doi: 10.1016/j.antiviral.2009.06.006
– ident: e_1_3_2_12_2
  doi: 10.1128/JVI.05779-11
– ident: e_1_3_2_34_2
  doi: 10.1146/annurev.iy.11.040193.001203
– ident: e_1_3_2_36_2
  doi: 10.1128/JVI.00756-10
– ident: e_1_3_2_13_2
  doi: 10.1016/j.vaccine.2013.06.073
– ident: e_1_3_2_18_2
  doi: 10.1038/nm1128
– ident: e_1_3_2_42_2
  doi: 10.1128/JVI.74.16.7651-7655.2000
– ident: e_1_3_2_14_2
  doi: 10.1016/j.vaccine.2011.08.098
– ident: e_1_3_2_15_2
  doi: 10.1016/j.vaccine.2008.09.016
– ident: e_1_3_2_23_2
  doi: 10.1038/sj.cgt.7700937
– ident: e_1_3_2_28_2
  doi: 10.1007/s00705-003-0006-z
– ident: e_1_3_2_25_2
  doi: 10.4049/jimmunol.172.10.6265
– ident: e_1_3_2_41_2
  doi: 10.1016/j.vaccine.2006.02.012
– ident: e_1_3_2_46_2
  doi: 10.1186/1471-2334-1-9
– ident: e_1_3_2_51_2
  doi: 10.1189/jlb.4MA0815-376RR
– ident: e_1_3_2_45_2
  doi: 10.1128/JVI.01997-08
– ident: e_1_3_2_50_2
  doi: 10.1038/ni1179
– ident: e_1_3_2_16_2
  doi: 10.1086/592507
– ident: e_1_3_2_30_2
  doi: 10.1371/journal.pone.0007428
– ident: e_1_3_2_7_2
  doi: 10.1006/viro.1998.9123
– ident: e_1_3_2_52_2
  doi: 10.1038/icb.2014.10
– ident: e_1_3_2_6_2
  doi: 10.1055/s-0028-1108143
– ident: e_1_3_2_9_2
  doi: 10.1099/0022-1317-79-5-1159
– ident: e_1_3_2_26_2
  doi: 10.1128/JVI.01042-17
– ident: e_1_3_2_2_2
  doi: 10.1128/JVI.00945-06
– ident: e_1_3_2_8_2
  doi: 10.1099/0022-1317-72-5-1031
– ident: e_1_3_2_22_2
  doi: 10.1089/10430340460745757
– ident: e_1_3_2_39_2
  doi: 10.1099/0022-1317-1-3-399
– ident: e_1_3_2_44_2
  doi: 10.1371/journal.pone.0149364
– ident: e_1_3_2_38_2
  doi: 10.1177/095632020101200105
– ident: e_1_3_2_33_2
  doi: 10.1128/jvi.70.12.8301-8309.1996
– volume: 12
  start-page: 124
  year: 2010
  ident: e_1_3_2_19_2
  article-title: MVA-85a, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults
  publication-title: Curr Opin Mol Ther
  contributor:
    fullname: Nicol MP
– ident: e_1_3_2_47_2
  doi: 10.1007/s00436-008-1150-x
– ident: e_1_3_2_55_2
  doi: 10.1002/9780471729259.mca04is17
– ident: e_1_3_2_24_2
  doi: 10.1099/vir.0.055921-0
– ident: e_1_3_2_43_2
  doi: 10.1371/journal.pone.0114374
– ident: e_1_3_2_29_2
  doi: 10.1371/journal.pone.0003043
– ident: e_1_3_2_53_2
  doi: 10.1128/JVI.01894-15
– ident: e_1_3_2_31_2
  doi: 10.1038/cmi.2014.128
– ident: e_1_3_2_27_2
  doi: 10.1155/2012/974067
– ident: e_1_3_2_4_2
  doi: 10.1128/JVI.02797-14
– ident: e_1_3_2_10_2
  doi: 10.1073/pnas.89.22.10847
– ident: e_1_3_2_17_2
  doi: 10.1073/pnas.0406381102
– volume: 17
  start-page: 124
  year: 1973
  ident: e_1_3_2_49_2
  article-title: Electron microscope study of the course of poxvirus officinale infection in cultures of alveolar macrophages
  publication-title: Acta Virol
  contributor:
    fullname: Jelinkova A
– volume: 167
  start-page: 375
  year: 1978
  ident: e_1_3_2_5_2
  article-title: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism
  publication-title: Zentralbl Bakteriol B
  contributor:
    fullname: Mayr A
– ident: e_1_3_2_32_2
  doi: 10.1038/s41598-017-08719-y
– ident: e_1_3_2_35_2
  doi: 10.1111/j.0818-9641.2004.01243.x
– ident: e_1_3_2_48_2
  doi: 10.1128/JVI.79.16.10397-10407.2005
– ident: e_1_3_2_37_2
  doi: 10.1099/vir.0.19285-0
SSID ssj0014464
Score 2.3803518
Snippet Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine...
Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Animals
CD4-Positive T-Lymphocytes - immunology
CD4-Positive T-Lymphocytes - virology
Chickens - immunology
Chickens - virology
Chlorocebus aethiops - immunology
Chlorocebus aethiops - virology
Cytokines - immunology
Genetic Vectors - immunology
Immunity, Cellular - immunology
Mice
Mice, Inbred BALB C
Pathogenesis and Immunity
Smallpox - immunology
Vaccination - methods
Vaccinia - immunology
Vaccinia - virology
Vaccinia virus - immunology
Viral Vaccines - immunology
Virulence - immunology
Title The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo
URI https://www.ncbi.nlm.nih.gov/pubmed/30567985
https://search.proquest.com/docview/2159321905
https://pubmed.ncbi.nlm.nih.gov/PMC6401461
Volume 93
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFL0CpEm8TGMbW8eHLtJ4TNt82EkeUQFREBMSXdW3yHZsLVKboDZF6p_ht3LtJAjGG89O7MjHH-fGx_cA_NapTAOec08nofQid88nDI0X5YrwjwNF71m1xR9-9Te6nrHZFrDuLowT7StZ9Mv5ol8W_5y28mGhBp1ObHB3O-KRTXniD7ZhmwZoF6K3RwcU30RdinCazbNO7R4kg-vpuE97Wup7vvXps-w5Tq2L8ust6R3P_F8u-Wr_ufwCn1viiGfNB-7Bli6_wqfGSnLzDZ4Ib5wWy7W7RISVwfPW-qTGqVCqKAvhyld472whVjheYbPgzTd4Z80Sls1_QawrnNjzAzxzytkNTio8p2h9UeXW7EujM603hcKRns-9W-f2oXMc27smGt0Ss3TqdWqkpFYfq-8wubyYjK681nvBU2ES1Z6QnNvuSYYs55ILqXgaM-vnZ0ImlIyJOigptDQyTIlzJGaoCXRmzFDlRof7sFNWpf4JGAiimLlNXScNsTUjYhaZkMI0f6glVdqD0673s4cmw0bmIpMgyQiwzAGW-UkPTjpoMpoC9lxDlLparzJiLcRCidmwHvxooHqpqcO4B_EbEF8esOm135bQqHNptttR9uvDbx7ALtGr1CrWfHYIO_VyrY-IwtTymMj7-ObYDdxnoBz0SQ
link.rule.ids 230,315,730,783,787,888,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswEB2kKYr20j2tu06B9ihZ-3IMnAZ2GgcBohq-CSRFokJtybDlBO7H9Fs7pKQgSU_teSRS0gzJR_HNPIDPMuWpFxWRJROfW4HJ8_F9ZQWFIP_HnqD7NNviLBp_D07m4XwPwj4XxpD2BS_tarG0q_KH4VaulmLY88SG59NRFOiSJ-7wHtyn8eoE_Sa9OzygHU7QFwkn-7znu3vJ8GQ2sWlVS13L1Up9Gj_HqdZRvrko_YU07xImb6xAx09g1j97Szz5aW8bbotfd8o6_vPLPYXHHSbFw9b8DPZk9RwetCqVuxfwm0IJZ-V6a_KTsFZ41KmqNDhjQpRVyYx9gxdGcWKDkw22c-lih-dah2Hd_nLEpsZMH03goSHl7jCr8ai-qpZ1oXXEJF6spGEJ4kguFtbUCInIAic6jUWimb3WhhhPnVTU62X9ErLjr9lobHWyDpbwk6CxGI8i_d0TJywiHjEuojQOtVSg8kMmeEyoRHAmueJ-SnAmUY6keAqVckShpH8A-1VdydeAHiP0WuiqeFwREFQsDgPl0w7QdSSnRgfwpXdrvmqLd-Rm0-MlOUVCbiIhd5MBfOp9ntPo0kcmrJL1dpMTICKAS6ApHMCrNgauW-qDZwDxrei4vkBX7r5tIZ-bCt6dj9_8950f4eE4m57mp5Ozb2_hEaG4VBPj3PAd7DfrrXxPSKnhH8y4-AMCYhVL
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgEYgL70d5DhIc806c5LhqqbYLu6q0paq4RLZji4jWqdoUVH4Mv5Wxk6y6y23PfiWZsf1N_Hk-Qj7KnOchLakjs4g7sb3nE0XKiUuB9k9Dge0M2-KcnnyLTxfJ4kDqy5L2Ba9cvVy5uvphuZXrlfB6npg3PRvS2KQ8Cbx1qbzb5A7OWZ_2gXp3gIBRTtwnCsfyRc95DzPvdD5xcWfLAycwan0GQ6e50VI-3Jj-Q5vXSZMHu9D4IfneP39LPvnp7hruij_XUjve6AUfkQcdNoXjtspjckvqJ-Ruq1a5f0r-okvBvNrs7D0lqBWMOnWVBuZMiEpXzJZv4cIqT2xhsoV2TV3uYWr0GDbtr0doapiZIwo4tuTcPcxqGNW_9aoujZ6YhIu1tGxBGMrl0jmzgiKyhIm5ziLBrmIbS5DHQTSO-qt-Rmbjz7PhidPJOzgiyuLGYZxS8-0zPykpp4wLmqeJkQxUUcIETxGdCM4kVzzKEdZkypfoV4lSviiVjJ6TI11r-ZJAyBDFliY7HlcICBVLk1hFGAkGvuTY6YB86k1brNskHoUNfsKsQG8orDcUQTYgH3q7FzjLzNEJ07LebQsERgh0ETwlA_Ki9YPLnnoHGpD0iodcVjAZvK-WoN1tJu_Ozq9u3PI9uTcdjYuvk_Mvr8l9BHO54ccFyRty1Gx28i0Cpoa_s1PjH57WF8s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Virulence+of+Different+Vaccinia+Virus+Strains+Is+Directly+Proportional+to+Their+Ability+To+Downmodulate+Specific+Cell-Mediated+Immune+Compartments+In+Vivo&rft.jtitle=Journal+of+virology&rft.au=de+Freitas%2C+Lorena+F+D&rft.au=Oliveira%2C+Rafael+P&rft.au=Miranda%2C+Mariana+C+G&rft.au=Rocha%2C+Ra%C3%ADssa+P&rft.date=2019-03-15&rft.eissn=1098-5514&rft.volume=93&rft.issue=6&rft_id=info:doi/10.1128%2FJVI.02191-18&rft_id=info%3Apmid%2F30567985&rft.externalDocID=30567985
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon